Name | mexiletine |
Synonyms | mexiletine 1-(2,6-Xylyloxy)-2-propylamine 1-(2,6-Dimethylphenoxy)propan-2-amine 1-(2,6-dimethylphenoxy)propan-2-amine 1-(2,6-Dimethylphenoxy)-2-Propanamine 1-(2',6'-Dimethylphenoxy)-2-aminopropane |
CAS | 31828-71-4 |
EINECS | 250-825-7 |
InChI | InChI:1S/C11H17NO/c1-8-5-4-6-9(2)11(8)13-7-10(3)12/h4-6,10H,7,12H2,1-3H3 |
Molecular Formula | C11H17NO |
Molar Mass | 179.25878 |
Density | 0.979±0.06 g/cm3(Predicted) |
Melting Point | 203-205 °C |
Boling Point | 271.5°C at 760 mmHg |
Flash Point | 112.2°C |
Water Solubility | ethanol: 50 mg/mL |
Vapor Presure | 0.00642mmHg at 25°C |
Storage Condition | 2-8°C |
Physical and Chemical Properties | Color white |
Use | Antiarrhythmic drugs, mainly used for the treatment of acute and chronic ventricular arrhythmias and Digitalis poisoning caused by arrhythmia |
Hazard Symbols | Xn - Harmful |
Risk Codes | R20/21/22 - Harmful by inhalation, in contact with skin and if swallowed. |
Safety Description | S36 - Wear suitable protective clothing. |
UN IDs | 3249 |
melting point | 203-205 °C |
boiling point | 271.5±28.0 °C(Predicted) |
density | 0.979±0.06 g/cm3(Predicted) |
storage conditions | 2-8°C |
solubility | ethanol: 50 mg/mL |
morphology | powder |
acidity coefficient (pKa) | pKa 9.14± 0.01(H2O,t =25±0.2, I =0.01(NaCl))(Approximate) |
color | white |
NIST chemical information | Mexiletine(31828-71-4) |
1. The combination of this product and commonly used anti-angina, anti-hypertensive and anti-fibrinolytic drugs has no interaction.
2. The combination of this product with quinidine, propranolol or amiodarone has a better therapeutic effect. It can be used for stubborn ventricular arrhythmias that are ineffective with a single drug, but it is not suitable for combination with class Ib drugs.
3. If phenytoin sodium or other liver enzyme inducers such as rifampicin and phenobarbital are combined with mexiletine, the blood concentration of this product can be reduced.
4. Benzodiazepines do not affect the blood concentration of this product.
5. The combination of this product with digoxin, diuretics and propranolol does not affect the PR, QRS and QT interval of electrocardiogram.
6. In the early stage of acute myocardial infarction, morphine delays and reduces the absorption of this product, which may be related to delayed gastric emptying.
7. Acid medicine can reduce the blood concentration when taking this product orally, but it can also increase the blood concentration due to the increase of urine pH.
1. The following conditions should be used with caution: hypotension, severe congestive heart failure, intraventricular block, severe sinus bradycardia, liver and kidney insufficiency.
2. Acute myocardial infarction can increase the mortality rate, so it should be used with caution.
3. It can cause severe arrhythmia, which mostly occurs in patients with malignant arrhythmia; it may worsen arrhythmia in patients with life-threatening arrhythmia.
4. Blood pressure, electrocardiogram and liver function should be monitored regularly during medication (especially for the elderly).
5. Patients with severe organic heart disease should be used with caution or not because they can increase the mortality rate.
chemical properties
When the product is used as an antiarrhythmic drug, its hydrochloride is mainly used. Hydrochloride is a white crystalline powder with a melting point of 203-205 ℃, soluble in water, slightly soluble in ethanol, acetone and insoluble in ether.
use
used as an antiarrhythmic agent.
production method
Starting from 2, 6-dimethylphenol.